Nature Communications (Oct 2018)
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
- Dominiek Smeets,
- Ian S. Miller,
- Darran P. O’Connor,
- Sudipto Das,
- Bruce Moran,
- Bram Boeckx,
- Timo Gaiser,
- Johannes Betge,
- Ana Barat,
- Rut Klinger,
- Nicole C. T. van Grieken,
- Chiara Cremolini,
- Hans Prenen,
- Massimiliano Mazzone,
- Jeroen Depreeuw,
- Orna Bacon,
- Bozena Fender,
- Joseph Brady,
- Bryan T. Hennessy,
- Deborah A. McNamara,
- Elaine Kay,
- Henk M. Verheul,
- Neerincx Maarten,
- William M. Gallagher,
- Verena Murphy,
- Jochen H. M. Prehn,
- Miriam Koopman,
- Cornelis J. A. Punt,
- Fotios Loupakis,
- Matthias P. A. Ebert,
- Bauke Ylstra,
- Diether Lambrechts,
- Annette T. Byrne
Affiliations
- Dominiek Smeets
- VIB Center for Cancer Biology
- Ian S. Miller
- Department of Physiology & Medical Physics, Royal College of Surgeons in Ireland
- Darran P. O’Connor
- Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland
- Sudipto Das
- Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland
- Bruce Moran
- UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin
- Bram Boeckx
- VIB Center for Cancer Biology
- Timo Gaiser
- Institute of Pathology, University Medical Center Mannheim, University of Heidelberg
- Johannes Betge
- Department of Medicine II, University Hospital Mannheim, Heidelberg University
- Ana Barat
- Department of Physiology & Medical Physics, Royal College of Surgeons in Ireland
- Rut Klinger
- UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin
- Nicole C. T. van Grieken
- Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam
- Chiara Cremolini
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Istituto Toscano Tumori
- Hans Prenen
- Department of Oncology, University Hospital Antwerp
- Massimiliano Mazzone
- VIB Center for Cancer Biology
- Jeroen Depreeuw
- VIB Center for Cancer Biology
- Orna Bacon
- Department of Physiology & Medical Physics, Royal College of Surgeons in Ireland
- Bozena Fender
- OncoMark Limited, NovaUCD
- Joseph Brady
- Veterinary Pathobiology, School of Veterinary Medicine, University College Dublin
- Bryan T. Hennessy
- Department of Surgery, Beaumont Hospital
- Deborah A. McNamara
- Department of Surgery, Beaumont Hospital
- Elaine Kay
- Department of Pathology, Beaumont Hospital
- Henk M. Verheul
- Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam
- Neerincx Maarten
- Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam
- William M. Gallagher
- UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin
- Verena Murphy
- Cancer Trials Ireland
- Jochen H. M. Prehn
- Department of Physiology & Medical Physics, Royal College of Surgeons in Ireland
- Miriam Koopman
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht University
- Cornelis J. A. Punt
- Department of Medical Oncology, Amsterdam UMC, University of Amsterdam
- Fotios Loupakis
- Oncologia Medica 1, Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, IRCCS
- Matthias P. A. Ebert
- Department of Medicine II, University Hospital Mannheim, Heidelberg University
- Bauke Ylstra
- Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam
- Diether Lambrechts
- VIB Center for Cancer Biology
- Annette T. Byrne
- Department of Physiology & Medical Physics, Royal College of Surgeons in Ireland
- DOI
- https://doi.org/10.1038/s41467-018-06567-6
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 16
Abstract
Increased copy number alterations, indicative of chromosomal instability, is associated with poor cancer outcome. Here, metastatic colorectal cancer patients displaying intermediate-high CIN associate with improved outcome following chemotherapy and bevacizumab treatment, suggesting CIN as a predictive biomarker.
